(3.239.33.139) 您好!臺灣時間:2021/02/27 00:43
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:施和均
研究生(外文):Ho-Jun Shih
論文名稱:IGFBP-3透過調控TSP-1的表現以抑制腫瘤的血管新生
論文名稱(外文):IGFBP-3 Regulates Angiogenesis through Up-Regulation of TSP-1
指導教授:林欽塘林欽塘引用關係
指導教授(外文):Chin-Tarng Lin
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:病理學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2010
畢業學年度:98
語文別:英文
論文頁數:53
中文關鍵詞:IGFBP-3TSP-1人類卵巢類子宮內膜癌腫瘤血管新生
外文關鍵詞:IGFBP-3TSP-1Angiogenesisovarian endometrioid carcinoma
相關次數:
  • 被引用被引用:0
  • 點閱點閱:281
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
類胰島素生長因子結合蛋白質-3 (IGFBP-3) 是個已知的抑癌基因。在人類卵巢類子宮內膜癌細胞株-OVTW59,具高度侵襲轉移能力的P4分株的IGFBP-3基因表現量明顯比原始的細胞株低 (Oncogene 2008; 27: 2137-47)。我們將帶有人類IGFBP-3基因的質體 (pKG3226-hIGFBP-3) 與空的質體轉殖到P4細胞株中,利用cDNA微陣列基因表達分析技術分析兩個轉殖細胞株的基因表現差異,我們發現,血小板反應蛋白質-1 (TSP - 1),一個內源性的血管生成抑製蛋白,與IGFBP-3有類似的基因表達模式。為了分析IGFBP-3與TSP-1之間的關係,我們建立一個利用四環黴素誘導 IGFBP-3的表達質體pBIG2i-hIGFBP-3轉殖到P4細胞株中。經由四環黴素刺激兩個小時後,IGFBP-3的表現量提高四倍,同時TSP-1的表現量也跟著增加。在人類的臍靜脈內皮細胞 (Human umbilical vein endothelial cell, HUVECs) 的管狀結構形成實驗中發現,IGFBP-3的表現會抑制管狀結構的形成;加入拮抗TSP-1抗體後,HUVECs的管狀結構形成能力會恢復。在雞胚絨毛尿囊膜 (chick embryo chorioallantoic membrane, CAM)試驗中,增加IGFBP-3的表現會抑制尿囊膜毛細血管的形成。在動物實驗中,利用四環黴素刺激IGFBP-3表達後5天,腫瘤的生長明顯被抑制,腫瘤的被抑制生長狀態持續了約 10天。在腫瘤切片免疫染色上發現,在生長抑制期間,除了腫瘤內微血管的密度減少,同時細胞凋亡增加。這些研究結果顯示,IGFBP-3可以透過調控TSP-1的表現,以抑制腫瘤血管的生成,使得腫瘤的生長受到抑制。這些實驗結果暗示, IGFBP-3及TSP-1可做為卵巢類子宮內膜癌之標的治療。

Insulin-like growth factor binding protein 3 (IGFBP-3) is known as an antiproliferative and an invasion-suppressor protein. In human ovarian endometrioid carcinoma (OEC) OVTW59, highly invasive subline P4 showed lower IGFBP-3 gene expression than the original P0 cell line (Oncogene 2008; 27:2137-47). By cDNA microarray analysis of differential gene expression between IGFBP-3 re-expression in P4-pKG3226-hIGFBP-3 transfectant and the control line, thrombospondin-1 (TSP-1) was identified to be significantly co-expression with IGFBP-3. TSP-1 is a known endogenous inhibitor of angiogenesis. We further established a tetracycline-inducible IGFBP-3 expressing OEC cell line using pBIG2i plasmid. This cell line showed 4-fold increase in IGFBP-3 expression 2 hours after tetracycline treatment in associated with a paraellel increase in TSP-1. In human umbilical vein endothelial cell (HUVECs) tube formation assay, IGFBP-3 expression was associated with a decrease in capillary tube formation. This reaction was reversed after anti-TSP-1 treatment. By chick embryo chorioallantoic membrane (CAM) assay, IGFBP-3 expression showed a significant decrease in capillary formation. Heterotransplantation of IGFBP-3-transfectants showed significant decrease in tumor growth 5 days after IGFBP-3 induction. The dormancy state of tumor growth persisted for about 10 days. Xenograft tumors in this period showed a decrease in micro vessel density and an increase in tumor apoptosis. In conclusion, we have identified a novel association between IGFBP-3 and TSP-1. IGFBP-3 could acts through the regulation of TSP-1 to decrease angiogenesis formation, and resulted in the dormancy state of cancer growth. By impairing the processes of angiogenesis, IGFBP-3 could then play as a tumor suppressor gene in ovarian cancer. Both IGFBP-3 and TSP-1 may serve for the molecular targeted therapy in patients with
ovarian endometroid cancer.

誌謝辭-------------------------------I
LIST OF ABBREVIATIONS----------------1
中文摘要-----------------------------2
ABSTRACT-----------------------------3
INTRODUCTION-------------------------4
MATERIALS AND METHODS----------------8
RESULTS-----------------------------16
DISCUSSION--------------------------20
REFERENCES--------------------------25
TABLES AND FIGURES ------------------31
APPENDIX----------------------------49

1.Achilles EG, Fernandez A, Allred EN, et al. Heterogeneity of angiogenic activity in a human iposarcoma: a proposed mechanism for “no take” of human tumors in mice. J. Natl. Cancer Inst. 2001; 93:1075–81.
2.Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 2007; 8(6), 464–78.
3.Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 1997; 94:861– 66.
4.Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. J Clin Pathol: Mol Pathol 2001; 54:145-48.
5.Bell KA and Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-defferentiated endometrioid adenocarcinomas of the ovary. The American journal of surgical pathology 2000; 24:1465-79.
6.Brem S, Brem H, Folkman J, et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 1976; 36:2807–12.
7.Bleuel K, Popp S, Fusenig NE, Stanbridge EJ, Boukamp P: Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 1999, 96:2065-2070
8.Cohen P, Lamson G, Okajima T and Rosenfeld RG. Transfection of the human IGFBP-3 gene into Balb/c fibroblasts: a model for the cellular function of IGFBPs. Growth Regul. 1993; 3: 23-6
9.Dabir P, Matinic TE, Krukovets I, Stenina OI. Aryl hydrocarbon receptor is activated by glucose and regulates the Thrombospondin-1gene promoter in endothelial cells. Circ Res. 2008;102:1558-65.
10.Flyvbjerg A, Mogensen O, Mogensen B and Nielsen OS. Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor. Endo. Oncol. 1997; 82: 2308-2313.
11.Folkman J. Incipient angiogenesis. J. Natl. Cancer Inst. 2000; 92:94–95.
12.Folkman J. Angiogenesis.,Annu. Rev. Med. 2006; 57:1-18.
13.Folkman J. “Tumour angiogenesis: therapeutic implications”, N. Engl. J. Med. 1971, 285, 1182–1186.
14.Gimbrone MA Jr, Leapman SB, Cotran RS, et al.Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 1972; 136:261–76.
15.Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, and Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis in immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci 1990; 87: 6624-6628.
16.Goodman MT, Correr CN, Tung KH, Roffers SD, Cheng Wu, Young JL Jr., Wilkens LR, Carney ME and Howe HL. Stage at dignosis of ovarian cancer un the United States, 1992-1997. Cancer 2003; 97: 2648-59
17.Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells". Cancer research 1997; 57(9): 1735–42.
18.Grimberg A. p53 and IGFBP-3: Apoptosis and cancer protection. Genetics and metabolism, 2000 (70): 85-98.
19.Haase VH. Hypoxia-inducible factors in the kidney. Am. J. Physiol. Renal Physiol. 2006; 291(2), F271–81.
20.Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353–64.
21.Health and vital statistic,2009. Government report of repartment of realth, Taiwan.
22.Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995; 1:149–53.
23.Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CYF, Wu HC, Lin CT. Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down- regulating SPARC gene expression. J. of Pathology, 2008 (214):445-455.
24.Hunt, T.K., Knighton, D.R., Thakral, K.K., Goodson, W.H. and Andrews, W.S. Studies on inflammation and wound healing: angiogenesis and collagen synthesis stimulated in vivo by resident and activated macrophages. Surgery 1984; 96, 48–54.
25.Jiang X, Morland SJ, Hitchcock A, Thomas EJ and Campbell IG. Allelotypring of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer research 1998; 58: 1707-12.
26.Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT, and Havemann K. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology, 1997;(138):1767-1770.
27.Katsaros D, Yu H, Levesque MA, et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer 2001; 37:478-85.
28.Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncology, 2005; 7(2), 134–53.
29.Kazerounian S, Yee KO and Lawler J. Thrombospondins in cancer. Cell. Mol. Life Sci. 2008; 65: 700 – 712.
30.Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006; 70(5), 1469–80.
31.Kim KS, Kim MS, Seu YB, Chung HY, Kim JH, and Kim JR. Regulation of replicative senescence by insulin-like growth factor-binding protein 3 in human umbilical vein endothelial cells. Aging Cell, 2007; 6: 535–545.
32.Kostecka Z, Blahovec J. Insuline-like growth factor binding proteins and their functions. Endocrine Regulation, 1999; (33):90-94.
33.Lawler J. The structural and functional properties of Thrombospondin. Blood, 1986; 67:1197-120.
34.Lawler J. The functions of Thrombospondin-1 and-2. Cell biology 2000; 12: 634-640.
35.Lawler J. and Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. The Inter. J of Biochem. And cell bio. 2004; 36:1038-45.
36.Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, and Keller GA. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology, 1997;(138):1763-1766.
37.Martin JL and Baxter RC. Insulin-like growth factor binding protein-3: Biochemistry and physiology. Growth Regulation, 1992; 2: 88-89.
38.MacDonald RG, Schaffer BS, Kang IG, Hong SM, Kim EJ and Park JH. Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3. J Gastroenterol Hepatol. 1999; 14: 72-8.
39.McGuire WP, Hoskins WJ, Brady MF, Kucera PR Partridge EE, Look KY. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol, 1996; 23:40-7.
40.Ohwada M, Suzuki M, Suzuki T, Hiratsuka M, Kawai T, Saito K. Problems with peritoneal cytology in second-look laparotomy performed in patients with epithelial ovarian carcinoma. Cancer, 2001; 93:376-80.
41.Panetti TS, Chen H, Misenheimer TM, Getzler SB, Mosher DF. Endothelial cell mitogenesis induced by LPA: Inhibition by thrombospondin-1 and thrombospondin-2. J. Lab Clin. Med., 1997; 129:208-16.
42.Plank, M.J., and Sleeman, B.D. Tumor-induced angiogenesis: a review. J. Theor. Med. 2003; 5: 137-153.
43.Ponce M.L. In vitro matrigel angiogenesis assay. Methods in Molecular Medicine, Vol. 46: Angiogenesis Protocols.
44.Radulescu RT. Nuclear localization signal in insulin-lie growth factor-binding protein type-3. Trends. Biochem. Sci., 1994;(19):278.
45.Rajah R, Balentinis B, Cohen P. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem, 1997 (272):12181-12188.
46.Roberts DD. Regulation of tumor growth an metastasis by thrombospondin-1. FASEB J. 1996 (10) :1183-1191.
47.Rodriguez-Manzaneque J C; Lane T F; Ortega M A; Hynes R O; Lawler J; and Iruela-Arispe M L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 2001; 98:12485-90.
48.Simpson JL and Bischoff FZ. Heritability and molecular genetic studies of endometriosis. Annals of the New York Academy of Sciences 2002; 955: 239-251, 293-235, 396-406.
49.Sheibani, N., and Frazier, W.A. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc. Natl. Acad. Sci. USA 1995; 92: 6788-6792
50.Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L., Lawler J., and Detmar M. 1999. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol. 1999; 155: 441.
51.Torng PL, Lee YCG, Huang CYF, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW, Lin CT. Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Acts as an Invasion-Metastasis Suppressor in Ovarian Endometrioid Carcinoma. Oncogene. 2007 27:(15)2137-2147.
52.Torng PL, Lin CW, Chan MWY, Yang HW, Huang SC, Lin CT. Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Mol Cancer. 2009 (8):120-131.
53.Udagawa T, Fernandez A, Achilles EG, et al. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J.2002; 16:1361–70.
54.Valentinis B, Bhala A, DeAngelis T, Baserga R, and Cohen P. The Human insulin-like growth factor (IGF) binding protein-3 inhibit the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Molec Endocrinol 1995 (9): 361-67.
55.van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 2008; 78(2), 203–12.
56.Volpert, OV , Lawler, J., and Bouck, NP (1997) A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental lung metastases via thrombospondin-1. Proc. Natl. Acas. Sci. USA. 1997; 95: 6343-6348
57.Wilting J., Christ B., and Bokeloh M. A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors. Anat Embryol. 1991; 183:259-271.
58.Zhao HY, Ooyama A,Yamamoto M, Ikeda R, Haraguchi M, Tabota S, Furukawa T, Che XF, Zhang S, Oka T, Fukushima M, Nakagawa M, Ono M, Kuwano M, and Akiyama SI. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res. 2008; 68(17):7035-41.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
1. 洪家殷,〈憲法解釋對行政罰法制發展之影響〉,憲政時代第31卷第4期,中華民國95年4月。
2. 林錫堯,〈淺析「行政罰法」草案〉,法學叢刊第192期,2003年10月。
3. 洪家殷,〈行政罰之處罰對象〉,月旦法學教室第90期,2010年4月。
4. 洪家殷,〈行政罰之概念與種類〉,月旦法學教室第84期,2009年10月。
5. 林三欽,〈將「專業簽證」納入「行政管制體系」後之國家責任問題──以建築簽證為例〉,月旦法學雜誌第151期,2007年12月。
6. 林明鏘,〈行政制裁(行政罰)〉,月旦法學雜誌第3期,1995年7月。
7. 李震山,〈論行政罰法「具裁罰性之不利處分」及「特別法優先適用原則」〉,法學叢刊第207期(第52卷第3期),2007年7月。
8. 洪家殷,〈行政罰之法律原則及效力〉,月旦法學教室第86期,2009年12月。
9. 林明鏘,〈論建造執照之審查與簽證──技術與行政分立制度?〉,月旦法學雜誌第151期,2007年12月。
10. 李建良,〈違法的正當娛樂──行政法上權利義務之繼受問題〉,月旦法學雜誌第14期,1996年7月。
11. 李建良,〈行政罰法中「裁罰性之不利處分」的概念意涵及法適用上之若干基本問題──「制裁性不利處分」概念之提出〉,月旦法學雜誌第181期,2010年6月。
12. 李建良,〈行政法上不當聯結禁止原則〉,月旦法學雜誌第82期,2002年3月。
13. 李介民,〈干涉行政法上整治責任之繼受及界限──以「土壤及地下水污染整治法」為範圍──兼評高雄高等行政法院九十三年度訴字第九四一號判決〉,中央警察大學警學叢刊第38卷第3期,民國96年11月。
14. 王毓正,〈論國家環境保護任務之私化〉,月旦法學雜誌第104期,2004年1月。
15. [16] 魏德樂、許耕原、郭明達、張勤振,多人沈浸式虛擬實境系統,「電腦與通訊」,第82期,69-73,1999。
 
系統版面圖檔 系統版面圖檔